INFI - Infinity Pharmaceuticals rises ~10% on upgrade indicating 'interesting opportunity' on lead asset

J.P. Morgan analyst Anupam Rama upgrades Infinity Pharmaceuticals ([[INFI]] +6.6%) to Neutral from Underweight, without a price target.The analyst expects positive data can lift negative sentiment on the shares.The analyst believes the company's lead asset eganelisib has an "interesting opportunity" in the immune checkpoint combination space, particularly for second-line advanced urothelial cancer.Shares currently trade at $4.05, +180% over the last one year.

For further details see:

Infinity Pharmaceuticals rises ~10% on upgrade indicating 'interesting opportunity' on lead asset